Development of a clinical model for ex vivo expansion of multiple populations of effector cells for adoptive cellular therapy

Cytotherapy

Volumn 10, Issue 1, 2008, Pages 30-37

  Meehan, K R ^a   Wu, J ^a   Webber, S M ^a   Barber, A ^a   Szczepiorkowski, Z M ^a   Sentman, C ^a  

^a NORRIS COTTON CANCER CENTER   (United States)

Author keywords

Adoptive therapy; Ex vivo; Expansion; Myeloma; Transplant

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; CYCLOPHOSPHAMIDE; INTERLEUKIN 2; OKT 3; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ISOLATION; CELL VIABILITY; CONTROLLED STUDY; CRYOPRESERVATION; CYTOTOXIC LYMPHOCYTE; CYTOTOXICITY; EFFECTOR CELL; EX VIVO STUDY; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN CELL; MYELOMA; MYELOMA CELL; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; STEM CELL MOBILIZATION;

EID: 38349177530     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1080/14653240701762398     Document Type: Article

References (26)

1. Attal, M., Harousseau, JL and Stoppa, AM (1996) A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med, 335, pp. 91-97.
2. Child, J., Morgan, G. and Davies, F. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. New Engl J Med, 348, pp. 1875-1883.
3. Tricot, G., Vesole, DH and Jagannath, S. (1996) Graft-versus-myeloma effect: Proof of principle. Blood, 87, pp. 1196-1198.
4. Reynolds, C., Ratanatharathorn, V. and Adams, P. (2001) Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma. Bone Marrow Transplant, 27, pp. 801-807.
5. Corradini, P., Voena, C. and Tarella, C. (1999) Molecular and clinical remission in multiple myeloma: Role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol, 17, pp. 208-215.
6. Porrata, LF, Gertz, MA and Geyer, SM (2004) The dose of infused lymphocytes in the autograft directly correlates with clinical outcome after autologous peripheral blood hematopoietic stem cell transplantation in multiple myeloma. Leukemia, 18, pp. 1085-1092.
7. Kay, NE, Leong, TL and Bone, N. (2001) Blood levels of immune cells predict survival in myeloma patients: Results of an Eastern Cooperative Oncology Group phase III trial for newly diagnosed multiple myeloma patients. Blood, 98, pp. 23-28.
8. Ito, M. and Shizuru, J. (1999) Graft-vs-lymphoma effect in an allogeneic hematopoietic stem cell transplantation model. Bio Blood Marrow Transplant, 5, pp. 357-368.
9. Rosinski, SL, McNiece, IK and Shpall, EJ (2005) Prognostic analysis of pre-transplant peripheral T-cell levels in patients receiving an autologous hematopoietic progenitor-cell transplant. Bone Marrow Transplant, 36, pp. 425-430.
10. Hess, AD, Bright, EC and Thoburn, C. (1997) Specificity of effector T lymphocytes in autologous graft-versus-host disease: Role of the major histocompatibility complex class II invariant chain peptide. Blood, 89, pp. 2203-2209.
11. Porrata, LF, Gertz, MA and Litzow, MR (2005) Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. Clin Cancer Res, 11, pp. 1210-1218.
12. Dudley, ME, Wunderlich, JR and Robbins, PF (2002) Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science, 298, pp. 850-854.
13. Dudley, ME, Wunderlich, JR and Nishirmura, MI (2001) Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother, 24, pp. 363-373.
14. Hu, HM, Poehlein, CH and Urba, WJ (2002) Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res, 62, pp. 3914-3919.
15. Porrata, LF, Gertz, MA and Inwards, DJ (2001) Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood, 98, pp. 579-585.
16. Powles, R., Singhal, S. and Treleaven, J. (1998) Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation. Blood, 91, pp. 3481-3486.
17. Pavletic, ZS, Joshi, SS and Pirruccello, SJ (1998) Lymphocyte reconstitution after allogeneic blood stem cell transplantation for hematologic malignancies. Bone Marrow Transplant, 21, pp. 33-41.
18. Wu, J., Ernstoff, MS and Hill, JM (2006) Ex vivo expansion of non-MHC restricted cytotoxic effector cells as adoptive immunotherapy for myeloma. Cytotherapy, 8, pp. 141-148.
19. + T cells. Blood, 103, pp. 3065-3072.
20. Zea, AH, Rodriguez, PC and Atkins, MB (2005) Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: A mechanism of tumor evasion. Cancer Res, 65, pp. 3044-3048.
21. Rodriguez, PC, Quiceno, DG and Zabaleta, J. (2004) Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res, 64, pp. 5839-5849.
22. Wen, WJ, Min, R. and Tricot, G. (2002) Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: Promising effector cells for immunotherapy. Blood, 99, pp. 3280-3285.
23. + T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection. Nat Med, 8, pp. 47-53.
24. + -selected hematopoietic cell transplantation. Blood, 102, pp. 2004-2013.
25. + T cells after high-dose chemotherapy for metastatic breast cancer. J Clin Oncol, 20, pp. 58-64.
26. Rapoport, AP, Levine, BL and Badros, A. (2004) Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cells. Bone Marrow Transplant, 33, pp. 53-60.